ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A
Drug: Carboxymethylcellulose Based Eye Drop Formulation B
Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
Drug: Carboxymethylcellulose Based Lubricant Eye Drops

First Posted Date: 2011-10-25

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 315

Registration Number: NCT01459588

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Phase 4

Completed

Conditions: Hypotrichosis

Interventions: Drug: bimatoprost ophthalmic solution 0.03%
Drug: bimatoprost vehicle solution

First Posted Date: 2011-10-07

Last Posted Date: 2013-05-22

Lead Sponsor: Allergan

Target Recruit Count: 88

Registration Number: NCT01448525

A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

Completed

Conditions: Macular Edema

Interventions: Drug: dexamethasone intravitreal implant 0.7 mg

First Posted Date: 2011-10-04

Last Posted Date: 2013-02-18

Lead Sponsor: Allergan

Target Recruit Count: 87

Registration Number: NCT01445626

BOTOX® Prophylaxis in Patients With Chronic Migraine

Completed

Conditions: Migraine Disorders

Interventions: Biological: botulinum toxin Type A

First Posted Date: 2011-09-13

Last Posted Date: 2019-01-08

Lead Sponsor: Allergan

Target Recruit Count: 1168

Registration Number: NCT01432379

Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion

Phase 4

Completed

Conditions: Retinal Vein Occlusion
Macular Edema

Interventions: Drug: dexamethasone intravitreal implant
Biological: ranibizumab

First Posted Date: 2011-09-02

Last Posted Date: 2019-04-18

Lead Sponsor: Allergan

Target Recruit Count: 307

Registration Number: NCT01427751

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

Phase 3

Terminated

Conditions: Glaucoma

Interventions: Drug: bimatoprost ophthalmic solution formulation A
Drug: timolol ophthalmic solution
Drug: bimatoprost vehicle

First Posted Date: 2011-08-31

Last Posted Date: 2015-10-02

Lead Sponsor: Allergan

Target Recruit Count: 6

Registration Number: NCT01426113

Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne

Phase 1

Withdrawn

Conditions: Acne Vulgaris

Interventions: Drug: Fixed Combination dapsone/adapalene Formulation A Gel
Drug: dapsone 5% gel
Drug: Fixed Combination dapsone/adapalene Formulation B Gel
Drug: adapalene 0.3% gel

First Posted Date: 2011-08-30

Last Posted Date: 2012-11-19

Lead Sponsor: Allergan

Registration Number: NCT01425320

Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale

Completed

Conditions: Healthy Volunteers

Interventions: Drug: No Intervention

First Posted Date: 2011-08-09

Last Posted Date: 2012-10-29

Lead Sponsor: Allergan

Target Recruit Count: 112

Registration Number: NCT01412086

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

Completed

Conditions: Retinal Vein Occlusion
Macular Edema

Interventions: Drug: dexamethasone intravitreal implant 0.7 mg

First Posted Date: 2011-08-08

Last Posted Date: 2013-04-16

Lead Sponsor: Allergan

Target Recruit Count: 289

Registration Number: NCT01411696

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

Phase 2

Completed

Conditions: Age-related Macular Degeneration

Interventions: Drug: AGN-150998
Drug: ranibizumab
Other: Sham Injection

First Posted Date: 2011-07-19

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 271

Registration Number: NCT01397409

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy